Figure 1.
Figure 1. The 3 different WT1 constructs used to generate mRNA for electroporation into DCs and their corresponding clinical responses and survival outcomes. Construct 1, WT1 (A); construct 2, WT1-DC-LAMP (B); and construct 3, WT1-DC-LAMP-OPT (C). Additional details have been reported by Benteyn et al.18 Median OS and 5-year OS percentage were calculated from the start of WT1/DC vaccination; values in brackets represent median follow-up. Full-color blue bars represent the remaining coding sequence of WT1 in constructs 2 and 3. The stable disease (SD) phase in UPN35 started during the administration of DCs electroporated with construct 3 (supplemental Table 1). MR, molecular remission; NLS, nuclear localization signal; undef, undefinable; UTR, untranslated region.

The 3 different WT1 constructs used to generate mRNA for electroporation into DCs and their corresponding clinical responses and survivaloutcomes. Construct 1, WT1 (A); construct 2, WT1-DC-LAMP (B); and construct 3, WT1-DC-LAMP-OPT (C). Additional details have been reported by Benteyn et al.18  Median OS and 5-year OS percentage were calculated from the start of WT1/DC vaccination; values in brackets represent median follow-up. Full-color blue bars represent the remaining coding sequence of WT1 in constructs 2 and 3. The stable disease (SD) phase in UPN35 started during the administration of DCs electroporated with construct 3 (supplemental Table 1). MR, molecular remission; NLS, nuclear localization signal; undef, undefinable; UTR, untranslated region.

Close Modal

or Create an Account

Close Modal
Close Modal